Drugs / CNT201
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07640425 | Jul 2024 → Jul 2027 expected | palmar fibromatosis | CONNEXT | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-02-23 | Pharmaceutical Research Network | 파마리서치, 코넥스트와 신약 후보물질 ‘CNT201’ 라이선스인 계약 체결 pharmaresearch.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNT201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07640425 ↗ |
| Modality | Protein / enzyme biologic | “CNT201: recombinant collagenase” NCT07640425 ↗ |